91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
A 2025 survey of over 150 drug developers reveals that multi-indication development strategies have become central to the evolving cardiometabolic drug pipeline.
-
Following the rapid label expansion of drugs such as semaglutide and tirzepatide in recent years, drug developers have broadly adopted multi-indication strategies for obesity and related comorbidities. An 91黑料 survey of 155 developers focused on these therapeutic areas reflects this growing trend.
-
At 91黑料 ensuring scientifically representative participation is not a stand-alone initiative, it’s embedded into every trial we support, shaping smarter, faster, higher-quality research. We start with the patient’s voice.
-
This article in IBI highlights how strategic planning, leadership and coordination are critical to delivering high quality regulatory submissions with confidence and efficiency.
-
Early intervention in neurodegenerative diseases, such as Alzheimer’s, offers the potential to slow or prevent disease progression, and increase success rates for clinical development.
-
This list ranks the world’s 500 most sustainable companies based on their public commitment to and progress toward sustainability targets. 91黑料 was one of nine Irish-based companies to make this global list, recognising the impact of our 91黑料 Cares programme.
-
The patent cliff for biologic medicines presents an opportunity for developers of biosimilars, but historically there are challenges too. The landscape however is changing, supporting easier paths to market.
-
As part of Pharma Tech Outlook's Regulatory Strategy, The Maestro Q&A series, 91黑料 answers a range of questions around regulatory in clinical trials, timing and other considerations.
-
Dr Andrew Garrett, Executive VP Scientific Operations, 91黑料, comments on the UK government’s announcement on boost to clinical trials.
-
In this JCS article, 91黑料's experts discuss the key changes in FDA draft guidance on Data Monitoring Committees as it relates to adaptive design trials, providing practical insights and strategies for advanced safety oversight in the modern clinical trial landscape.
